Provision of Antioxidant Therapy in Hemodialysis (PATH) Study

Launched by VANDERBILT UNIVERSITY · Oct 10, 2005

Keywords

ClinConnect Summary

Oxidative stress and acute phase inflammation are now recognized to be highly prevalent in the hemodialysis population, and several lines of evidence point to their contribution in atherosclerosis development. Biomarkers of the inflammatory state such as C-reactive protein (CRP) and interleukin-6 are robust predictors of cardiovascular events and mortality in the dialysis population. The uremic state is characterized by retention of oxidized solutes including reactive aldehyde groups and oxidized thiol groups. It has recently been demonstrated that initiation of maintenance hemodialysis doe...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with end-stage renal disease receiving thrice weekly hemodialysis
• • 2. Age \> 18 years
• • 3. Life expectancy greater than one year
• • 4. Ability to understand and provide informed consent for participation in the study
• Exclusion Criteria:
• • 1. AIDS (HIV seropositivity is not an exclusion criteria)
• • 2. Active malignancy excluding basal cell carcinoma of the skin
• • 3. Gastrointestinal dysfunction requiring parenteral nutrition
• • 4. History of functional kidney transplant \< 6 months prior to study entry
• • 5. Anticipated live donor kidney transplant over study duration
• • 6. History of poor adherence to hemodialysis or medical regimen
• • 7. Prisoners, patients with significant mental illness, pregnant women, and other vulnerable populations
• • 8. Patients taking vitamin E supplements \> 60 IU/day, vitamin C \> 500 mg/day over the past 30 days
• • 9. Patients taking anti-inflammatory medication except aspirin \< 325 mg/day over the past 30 days
• • 10. Patients using a temporary catheter for dialysis access
• • 11. More than two hospitalizations within the last 90 days or one hospitalization within the last 30 days